Skip to main content

Table 2 Steady-state serum and alveolar TGC PK parameters in the 32 enrolled patients

From: Pharmacokinetics of high-dose tigecycline in critically ill patients with severe infections

Parameter Patients (n = 32)
Vd, L 438.6
CL, L/h 42.1
t1/2, h 7.2
Cmax, mcg/mL 0.34 [0.15–1.03]
Cmin, mcg/mL 0.09 [0.05–0.26]
ELF Cmax, mcg/mL* 0.42 [0.15–1.2]
ELF Cmin, mcg/mL* 0.32 [0.17–0.43]
ELF/plasma ratio (%), median [IQR]* 152.9 [73.5–386.8]
AUC0-24, mcg h/mL 3.61 [2.55–10.39]
AUC0-24/0.12 mcg/mL MIC ≥ 4.5, (%) 100
AUC0-24/0.25 mcg/mL MIC ≥ 4.5, (%) 94
AUC0-24/0.5 mcg/mL MIC ≥ 4.5, (%) 75
AUC0-24/1 mcg/mL MIC ≥ 4.5, (%) 40.6
AUC0-24/2 mcg/mL MIC ≥ 4.5, (%) 28.1
AUC0-24/0.12 mcg/mL MIC ≥ 6.96, (%) 100
AUC0-24/0.25 mcg/mL MIC ≥ 6.96, (%) 91
AUC0-24/0.5 mcg/mL MIC ≥ 6.96, (%) 50
AUC0-24/1 mcg/mL MIC ≥ 6.96, (%) 34.4
AUC0-24/2 mcg/mL MIC ≥ 6.96, (%) 15.6
AUC0-24/0.12 mcg/mL MIC ≥ 17.9, (%) 78
AUC0-24/0.25 mcg/mL MIC ≥ 17.9, (%) 44
AUC0-24/0.5 mcg/mL MIC ≥ 17.9, (%) 25
AUC0-24/1 mcg/mL MIC ≥ 17.9, (%) 9.4
AUC0-24/2 mcg/mL MIC ≥ 17.9, (%) 3.1
  1. Data are expressed as median [IQR] and N (%)
  2. TGC tigecycline; PK pharmacokinetic; Vd volume of drug distribution, IQR interquartile range; CL drug clearance; t1/2 elimination half-life; Cmax peak plasmatic concentration; Cmin trough plasmatic concentration; ELF epithelial lining fluid; MIC minimum inhibitory concentration; AUC total drug area under the time–concentration curve
  3. *TGC ELF concentrations were measured in 12 (1 h) and 7 (12 h) samples, respectively